Basilea Pharmaceutica AG (BSLNz)

Currency in CHF
51.90
0.00(0.00%)
Closed·
BSLNz Scorecard
Full Analysis
Valuation implies a strong free cash flow yield
Earnings results expected in 8 days
BSLNz is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
51.3052.50
52 wk Range
37.6559.70
Key Statistics
Bid/Ask
51.70 / 51.90
Prev. Close
51.9
Open
52.3
Day's Range
51.3-52.5
52 wk Range
37.65-59.7
Volume
3.33K
Average Volume (3m)
4.55K
1-Year Change
34.72%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BSLNz Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Cash flows can sufficiently cover interest payments

Basilea Pharmaceutica AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Basilea Pharmaceutica AG Company Profile

Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Compare BSLNz to Peers and Sector

Metrics to compare
BSLNz
Peers
Sector
Relationship
P/E Ratio
8.3x−2.8x−0.5x
PEG Ratio
0.01−0.030.00
Price/Book
8.0x3.2x2.6x
Price / LTM Sales
3.1x6.4x3.3x
Upside (Analyst Target)
-25.6%43.3%
Fair Value Upside
Unlock12.7%6.9%Unlock

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BSLNz Income Statement

People Also Watch

31.91
UBSG
-0.09%
627.00
ASML
+1.64%
96.02
NOVN
+2.08%
78.78
LOGN
-1.03%

FAQ

What Stock Exchange Does Basilea Pharmaceutica AG Trade On?

Basilea Pharmaceutica AG is listed and trades on the BATS Europe stock exchange.

What Is the Stock Symbol for Basilea Pharmaceutica AG?

The stock symbol for Basilea Pharmaceutica AG is "BSLNz."

What Is the Basilea Pharmaceutica AG Market Cap?

As of today, Basilea Pharmaceutica AG market cap is 635.49M.

What Is Basilea Pharmaceutica AG's Earnings Per Share (TTM)?

The Basilea Pharmaceutica AG EPS (TTM) is 6.42.

When Is the Next Basilea Pharmaceutica AG Earnings Date?

Basilea Pharmaceutica AG will release its next earnings report on 18 Aug 2025.

From a Technical Analysis Perspective, Is BSLNz a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Basilea Pharmaceutica AG Stock Split?

Basilea Pharmaceutica AG has split 0 times.

How Many Employees Does Basilea Pharmaceutica AG Have?

Basilea Pharmaceutica AG has 164 employees.

What is the current trading status of Basilea Pharmaceutica AG (BSLNz)?

As of 11 Aug 2025, Basilea Pharmaceutica AG (BSLNz) is trading at a price of 51.90, with a previous close of 51.90. The stock has fluctuated within a day range of 51.30 to 52.50, while its 52-week range spans from 37.65 to 59.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.